Third, recognize the value of Jae's unique background. As an immigrant who has achieved success through hard work and dedication, Jae brings a valuable perspective to the bench that can enhance ...

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up ...